TG Therapeutics(TGTX) - 2025 Q1 - Quarterly Results

Financial Performance - BRIUMVI U.S. net product revenue for Q1 2025 was $119.7 million, representing approximately 137$575 million, up from prior guidance of $540 million[8] - The U.S. net revenue target for BRIUMVI for the full year 2025 was raised to approximately$560 million, compared to the previous target of $525 million[8] - TG Therapeutics reported total revenue of$120.856 million for the three months ended March 31, 2025, a 90.5% increase from $63.474 million in the same period of 2024[41] - Product revenue, net for the same period was$119.655 million, compared to $50.488 million in the prior year, reflecting a significant growth of 137.4$8.622 million in Q1 2025, compared to an operating loss of $9.270 million in Q1 2024[41] - Net income for the first quarter of 2025 was$5.060 million, a turnaround from a net loss of 10.707 million in the same quarter of 2024[41] Expenses - Total research and development (R&D) expenses for Q1 2025 were 46.4 million, an increase from 32.7 million in Q1 2024[8] - Selling, general and administrative (SG&A) expenses for Q1 2025 were 50.3 million, compared to $34.6 million in Q1 2024[8] Cash and Assets - Cash, cash equivalents, and investment securities were$276.2 million as of March 31, 2025, expected to fund operations based on the current plan[8] - Cash, cash equivalents, and investment securities totaled $276.240 million as of March 31, 2025, down from$311.001 million at the end of 2024[42] - Total assets increased to $656.689 million as of March 31, 2025, compared to$577.690 million at the end of 2024[42] - Total equity rose to $237.288 million as of March 31, 2025, up from$222.364 million at the end of 2024[42] Product Development and Commercialization - BRIUMVI is now commercially available in additional countries in the European Union, United Kingdom, and Switzerland[5] - The company is advancing the development of subcutaneous BRIUMVI and azer-cel for progressive MS[2] - A pivotal program for subcutaneous BRIUMVI is set to commence, along with a program based on improved dosing regimens evaluated in the ENHANCE trial[8] - The company is focused on the commercialization of BRIUMVI® (ublituximab-xiiy) for relapsing forms of multiple sclerosis, with approvals in the U.S., EU, UK, and Switzerland[32] Future Outlook - Future revenue expectations for BRIUMVI are contingent on healthcare professional and patient acceptance, as well as maintaining prescription trends[36] - TG Therapeutics anticipates achieving key development milestones for its pipeline products by 2025, including pivotal programs for subcutaneous ublituximab[37]